Dr. Kevin B. Merkes

Internal Medicine
North County Internists Medical Corp.
15721 Pomerado Rd, 
Poway, CA 
Offers Telehealth
North County Internists Medical Corp.
15721 Pomerado Rd, 
Poway, CA 

Overview

Kevin Merkes is a primary care provider, practicing in Internal Medicine in Poway, California.

His clinical expertise encompasses Benign Paroxysmal Positional Vertigo, Pneumonia, Type 2 Diabetes (T2D), and Sitosterolemia.

He is actively involved in clinical research, participating in 10 clinical trials.

Specialties

Internal Medicine

Licenses

Geriatric Medicine in CA

Hospital Affiliations

Palomar Medical Center Poway
Palomar Health Downtown Campus

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

North County Internists Medical Corp.
15721 Pomerado Rd, Poway, CA 92064

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Device, Diagnostic test
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: August 06, 2020
Intervention Type: Other
View 9 Less Clinical Trials
Similar Doctors
Expertise in
19
conditions
Dr. Arthur F. Kavanaugh
Internal Medicine
Expertise in
19
conditions
Dr. Arthur F. Kavanaugh
Internal Medicine
Before you request

UC San Diego Health Clinical Laboratory-La Jolla

9350 Campus Point Dr, 
La Jolla, CA 
 (12.9 miles away)
800-926-8273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arthur Kavanaugh is a primary care provider, practicing in Internal Medicine in La Jolla, California. Dr. Kavanaugh is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Psoriatic Arthritis, Arthritis, Psoriasis, and Necrosis. Dr. Kavanaugh is currently accepting new patients.

Expertise in
13
conditions
Dr. Bruce L. Zuraw
Internal Medicine
Expertise in
13
conditions
Dr. Bruce L. Zuraw
Internal Medicine

UC San Diego

200 W Arbor Dr, 
San Diego,, CA 
 (18.1 miles away)
858-657-8322
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce Zuraw is a primary care provider, practicing in Internal Medicine in San Diego,, California. Dr. Zuraw is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Angioedema, Hereditary Angioedema, Hives, Asthma, and Hormone Replacement Therapy (HRT).

Expertise in
13
conditions
Dr. Fouad J. Moawad
Internal Medicine
Expertise in
13
conditions
Dr. Fouad J. Moawad
Internal Medicine

Scripps Clinic John R. Anderson V Medical Pavilion

9898 Genesee Ave, 
La Jolla, CA 
 (12.5 miles away)
858-824-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fouad Moawad is a primary care provider, practicing in Internal Medicine in La Jolla, California. Dr. Moawad is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Esophagitis, Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Kevin B. Merkes

How do I make an appointment with Dr. Kevin B. Merkes?

You can book an appointment with Dr. Kevin B. Merkes by calling their office at 619-295-9494. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kevin B. Merkes a top-rated expert for Benign Paroxysmal Positional Vertigo?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kevin B. Merkes is classified as an Experienced expert for Benign Paroxysmal Positional Vertigo, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kevin B. Merkes specialize in?

While Dr. Kevin B. Merkes is a Internal Medicine, they have specific expertise in Benign Paroxysmal Positional Vertigo, Pneumonia, and Type 2 Diabetes (T2D). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Kevin B. Merkes accept my insurance?

Dr. Kevin B. Merkes accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 619-295-9494 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Merkes's expertise for a condition
ConditionClose
        View All 49 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile